OakChart

MapLight Therapeutics Inc

MPLTHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 10:18 AM ET

7.62+0.18 (2.43%)
2026-11-11 16:18 CET
Market cap
413.48 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-229.83 USD m
Free cash flow, TTM
-175.12 USD m
EPS diluted, TTM
-5.12
P/E
-
Compare

Price

MPLT against its 20, 50 and 200-day averages
2050200beatmiss
10.0020.0030.0040.004.1M8.1MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MPLTclose 7.6220-day 7.5650-day 9.58200-day 20.087.62

81.2% under 40.43 on 10 Jul 2026. Last 15 sessions, 40.0% high to low

Profile

MPLT
52-week range, 5% of the way up
6.0640.43

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. It develops the ML-007-MA product for treatment of schizophrenia and ADP. Its platforms include Optogenetics, Transcriptnomics, and STARmap. The company was founded by Christopher A. Kroeger, Karl Deisseroth, Robert Malenka, and Karoly Nikolich in November 2018 and is headquartered in Redwood City, CA.

IndexRUT
Employees133
IPOOct 27, 2025
Beta2.97
ATR, 14d0.63
Rel volume0.34
Short float26.63%
Insider own78.03%
Inst own27.29%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap423.53M
Enterprise Value120.79M
Income-229.83M
Sales0.00M
Book/sh7.67
Cash/sh5.48
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees133
IPOOct 27, 2025

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.99
P/C1.39
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio16.52
Current Ratio16.52
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-5.12
EPS next Y-4.12
EPS next Q-1.18
EPS this Y73.54%
EPS next Y16.17%
EPS next 5Y40.14%
EPS past 3/5Y-71.59% -
Sales past 3/5Y- -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-83.91%
Sales Q/Q-
EarningsAug 13 AMC
EPS/Sales Surpr.2.16% -

Ownership

Insider Own78.03%
Insider Trans12.87%
Inst Own27.29%
Inst Trans-1.34%
ROA-101.59%
ROE-111.55%
ROIC-65.84%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA200.78%
SMA50-20.47%
SMA200-62.05%
Trades-

Technical

Shs Outstand45.44M
Shs Float12.21M
Short Float26.63%
Short Ratio6.77
Short Interest3.25M
52W High40.43 -81.15%
52W Low6.06 25.76%
Volatility10.40% 8.21%
ATR (14)0.63
RSI (14)43.99
Beta2.97
Rel Volume0.34
Avg Volume480.38K
Volume26,912

Performance

Perf Week13.58%
Perf Month-3.23%
Perf Quarter-34.19%
Perf Half Y-75.15%
Perf YTD-56.61%
Perf Year-49.43%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.50
Target Price25.30
Prev Close7.44
Price7.62
Change %2.43%

Analyst ratings

latest 10 of 15
DateActionAnalystRating changeTargetImplied
Oct 06, 2026InitiatedGGuggenheimNeutral
Aug 10, 2026DowngradeUUBSBuy → Neutral$13+70.6%
Jul 28, 2026DowngradeMMorgan StanleyOverweight → Equal-Weight$21+175.6%
Jul 21, 2026InitiatedBBMO Capital MarketsOutperform$46+503.6%
Jun 25, 2026InitiatedRRaymond JamesStrong Buy$46+503.6%
May 27, 2026InitiatedUUBSBuy$48+529.8%
May 21, 2026InitiatedCCraig HallumBuy$43+464.2%
May 04, 2026InitiatedHH.C. WainwrightBuy$45+490.5%
Apr 08, 2026InitiatedNNeedhamBuy$37+385.5%
Apr 07, 2026InitiatedTTD CowenBuy

Peers

Mkt cap
TickerCompanyMkt cap
LBRXLB Pharmaceuticals Inc1.46B
ACADAcadia Pharmaceuticals Inc3.17B
NMRANeumora Therapeutics Inc86.32M
BMYBristol-Myers Squibb Co125.63B
ANROAlto Neuroscience Inc1.17B
NBIXNeurocrine Biosciences Inc17.30B
CTNMContineum Therapeutics Inc422.70M
AXSMAxsome Therapeutics Inc7.79B
ABBVAbbvie Inc514.51B
PRTAProthena Corp Plc441.09M

Insider trading

latest 14 of 100
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Kreitzer AnatolChief Discovery OfficerOct 15 '26Sale7.8412,24896,024168,678Oct 16 05:00 PM
GILLIS JONATHANCAO and Interim CFOOct 15 '26Sale8.0810,16782,149142,315Oct 16 05:00 PM
Lillie James WoodruffChief Scientific OfficerOct 15 '26Sale8.0811,51393,025198,597Oct 16 05:00 PM
Hanson KristopherGeneral CounselOct 15 '26Sale8.089,02072,882128,024Oct 16 05:00 PM
Foff Erin PennockChief Medical OfficerOct 15 '26Sale8.0815,355124,068296,906Oct 16 05:00 PM
Kroeger Christopher A.Chief Executive OfficerOct 15 '26Sale8.0873,691595,4231,195,909Oct 16 05:00 PM
Hanson KristopherOfficerOct 15 '26Proposed Sale7.819,02070,446Oct 15 06:35 PM
GILLIS JONATHANOfficerOct 15 '26Proposed Sale7.8110,16779,404Oct 15 05:44 PM
Foff Erin PennockOfficerOct 15 '26Proposed Sale7.8115,355119,922Oct 15 05:30 PM
Kroeger Christopher A.OfficerOct 15 '26Proposed Sale7.8173,691575,527Oct 15 05:26 PM
Lillie James WoodruffOfficerOct 15 '26Proposed Sale7.8111,51389,917Oct 15 05:15 PM
ROBERT MALENKADirectorOct 15 '26Proposed Sale7.8114,809115,658Oct 15 04:37 PM
Anatol KreitzerOfficerOct 15 '26Proposed Sale7.8112,50097,625Oct 15 04:09 PM
Hanson KristopherGeneral CounselSep 16 '26Sale11.6716,509192,660137,044Sep 18 04:15 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
VHTVanguard Health Care ETFAUM: 21.51B
IWCiShares Micro-Cap ETFAUM: 1.22B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B

News

latest 14 of 56
  • MapLight Therapeutics to Participate in Upcoming Investor Conference (GlobeNewswire) +5.05%
  • MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics (GlobeNewswire)
  • MapLight Therapeutics to Participate in Upcoming Investor Conference (GlobeNewswire)
  • AstraZenecas win in lung cancer; Sandoz inks a China deal (BioPharma Dive) +5.11%
  • AstraZeneca scores in lung cancer; Sandoz inks a China deal (BioPharma Dive)
  • Loading…
  • MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • MapLight Therapeutics Announces $150 Million Private Placement Financing (GlobeNewswire)
  • MapLight CEO on what investors missed in the biotechs schizophrenia data (BioPharma Dive) +22.01%
  • MapLight Therapeutics stock crashes on Phase II schizophrenia data (Clinical Trials Arena) +24.28%
  • MPLT Stock Plunges 73% Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose (Stocktwits) -72.91%
  • MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia (GlobeNewswire)
  • Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls (The Fly)
  • MapLight Therapeutics Announces Changes to Board of Directors (GlobeNewswire) +7.02%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-1.320-1.349-1.3200.000.0013
2026Q12026-05-14-1.340-1.048-1.3420.000.009
2025Q42026-03-26-2.470-0.962-1.8070.000.005
2025Q32025-12-04-37.180-1.725-0.6480.000.004
2025Q22025-09-03-1.507--0.7200.00--
2026Q3---1.183--0.0012
2026Q4---1.175--0.0012
2027Q1---1.128--0.007
2027Q2---1.097--0.007
2027Q3---1.127--0.007
2027Q4---1.162--0.007

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY-18.560-7.078-18.5860.000.00
2026FY--4.911--0.00
2027FY--4.117--0.00
2028FY--3.981--0.00
2029FY--3.728--10.83
2030FY--3.461--60.16

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-045000.000.000.00
2026Q3S2026-10-166000.000.000.00
2026Q3S2026-08-237000.000.000.00
2026Q3S2026-08-148000.000.000.00
2026Q3S2026-08-138000.000.000.00
2026Q3S2026-07-088000.000.000.00
2026Q3S2026-07-047000.000.000.00
2026Q3S2026-06-238000.000.000.00
2026Q3S2026-05-207000.000.000.00
2026Q3S2026-05-156000.000.000.00
2026Q3S2026-05-016000.000.000.00
2026Q3S2026-04-075000.000.000.00
2026Q3S2026-04-064000.000.000.00
2026Q3S2026-03-263000.000.000.00

Estimate history

EPS, annual-0.725-1.345-1.873-3.661-5.1221
Period2022202320242025TTM
EPS, quarterly-0.289-0.457-0.444-0.539-0.72-0.648-1.807-1.342-1.325
PeriodQ1 '23Q1 '24Q2 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00000
Period2022202320242025TTM
Sales, quarterly000000000
PeriodQ1 '23Q1 '24Q2 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual41.42941.42941.42944.02445.437
Period2022202320242025MRQ
Shares, quarterly41.42941.42941.42941.42941.42945.37344.02445.20945.437
PeriodQ1 '23Q1 '24Q2 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Total Revenue0.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.580.580.700.560.57
Gross Profit-0.58-0.58-0.70-0.56-0.57
Selling, General and Administrative Excl. Other242.34168.5082.2556.7330.67
Research and Development198.70138.3567.8249.1226.57
Other Operating Expense0.000.000.000.000.00
Operating Income-242.93-169.08-82.95-57.28-31.25
Interest Expense0.000.000.000.000.00
Unusual Expense0.000.000.000.51-0.80
Net Income Before Taxes-229.83-161.15-77.58-55.71-30.02
Income Taxes0.000.000.000.000.00
Consolidated Net Income-229.83-161.15-77.58-55.71-30.02
Net Income From Continuing Operations-229.83-161.15-77.58-55.71-30.02
Net Income-229.83-161.15-77.58-55.71-30.02
EPS (Recurring)-5.06-3.66-1.87-1.34-0.74
EPS (Basic, Before Extraordinaries)-5.12-3.66-1.87-1.34-0.72
EPS (Diluted)-5.12-3.66-1.87-1.34-0.72
EBITDA-242.34-168.50-82.25-56.73-30.67
Non-Operating Income (Expense)13.107.935.372.090.43
Other After Tax Adjustments0.000.000.000.000.00
Stock Option Compensation Expense53.9136.011.081.041.36
Shares Outstanding45.4444.0241.4341.4341.43
Market Capitalization413.48413.48813.54--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q22024Q1
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.150.160.140.140.140.170.170.15
Gross Profit-0.15-0.16-0.14-0.14-0.14-0.17-0.17-0.15
Selling, General and Administrative Excl. Other63.4064.3483.2431.3630.5323.3819.8119.14
Research and Development53.4453.6864.6226.9626.7119.6215.4715.20
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-63.55-64.50-83.38-31.50-30.66-23.54-19.98-19.29
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.00-
Net Income Before Taxes-60.19-60.67-79.55-29.42-29.85-22.34-18.40-18.93
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-60.19-60.67-79.55-29.42-29.85-22.34-18.40-18.93
Net Income From Continuing Operations-60.19-60.67-79.55-29.42-29.85-22.34-18.40-18.93
Net Income-60.19-60.67-79.55-29.42-29.85-22.34-18.40-18.93
EPS (Recurring)-1.32-1.34-1.81-0.65-0.72-0.54-0.44-0.46
EPS (Basic, Before Extraordinaries)-1.32-1.34-1.81-0.65-0.72-0.54-0.44-0.46
EPS (Diluted)-1.32-1.34-1.81-0.65-0.72-0.54-0.44-0.46
EBITDA-63.40-64.34-83.24-31.36-30.53-23.38-19.81-19.14
Non-Operating Income (Expense)3.363.833.832.080.821.201.580.36
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.639.6435.520.120.150.210.240.27
Shares Outstanding45.4445.2144.0245.3741.4341.4341.4341.43
Market Capitalization413.48862.73796.98813.54----

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY
Cash & Short Term Investments305.10108.8079.7727.66
Short Term Receivables0.000.000.000.00
Inventories0.000.000.000.00
Other Current Assets19.575.813.834.37
Total Current Assets324.67114.6083.6032.03
Net Property, Plant & Equipment6.587.566.587.12
Total Investments and Advances148.2011.591.220.23
Intangible Assets-0.000.000.00
Other Assets0.063.170.000.00
Total Assets479.51136.9291.4139.39
Short Term Debt Incl. Current Port. of LT Debt0.890.780.490.35
Accounts Payable0.000.000.000.00
Other Current Liabilities15.3415.1414.2012.25
Total Current Liabilities16.2315.9214.7012.60
Long Term Debt4.915.805.435.92
Provision for Risks Charges0.000.000.000.00
Other Liabilities0.000.000.000.00
Total Liabilities21.1421.7220.1318.52
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.00308.82188.8783.83
Common Equity458.37-193.63-117.58-62.96
Total Shareholders Equity458.37115.1971.2820.87
Accumulated Minority Interest0.000.000.000.00
Total Equity458.37115.1971.2820.87
Total Liabilities & Stockholders Equity479.51136.9291.4139.39
Book Value Per Share10.41-4.67-2.84-1.52
Tangible Book Value Per Share10.41-4.67-2.84-1.52
Full-Time Employees133-63-
Price to Book Ratio0.97-2.97--
Return on Assets-52.29-67.96-85.18-
Return on Equity-56.19-83.21-120.91-
Return on Invested Capital-34.78-64.12-72.62-112.03
Quick Ratio20.017.205.692.54
Current Ratio20.017.205.692.54

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Net Income-229.83-161.15-77.58-55.71-30.02
Depreciation0.580.580.700.560.57
Other Funds (Non Cash)51.0935.271.131.111.14
Funds from Operations-178.16-125.30-75.75-54.05-28.30
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital3.49-12.84-3.062.041.72
Cash from Operating Activities-174.67-138.14-78.81-52.01-26.58
Capital Expenditures-0.45-0.47-0.77-0.46-0.75
Net Assets From Acquisitions0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.00
Purchase or Sale of Investments-249.98-322.73-80.020.000.00
Purchase of Investments-428.01-408.23-125.020.000.00
Sale Or Maturity of Investments178.0385.5045.000.000.00
Other Uses0.000.000.000.000.00
Other Sources0.000.000.000.000.00
Cash from Investing Activities-250.43-323.21-80.79-0.46-0.75
Cash Dividends Paid0.000.000.000.000.00
Change in Capital Stock475.58474.84120.25104.5733.17
Repurchase of Common Pref Stock0.000.000.000.000.00
Sale of Common Pref Stock475.58474.84120.25104.5733.17
Proceedsfrom Stock Options475.21474.56119.96104.5333.16
Issuance or Reduction of Debt, Net0.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.00
Net Financing Active Other Cash Flow-12.31-5.02-2.190.000.00
Other Financing Activities Uses-12.31-5.02-2.190.000.00
Cash from Financing Activities463.26469.82118.06104.5733.17
Net Change in Cash38.178.48-41.5452.105.85
Free Cash Flow-175.12-138.61-79.58-52.47-27.32
Preferred Dividends (Cash Flow)-0.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments304.73310.11305.10227.1760.4792.26
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets14.0617.1119.5718.1412.736.00
Total Current Assets318.79327.23324.67245.3173.2098.26
Net Property, Plant & Equipment2.506.236.586.576.907.18
Total Investments and Advances46.8285.30148.200.210.212.70
Intangible Assets---0.000.000.00
Other Assets0.240.040.065.143.813.42
Total Assets368.35418.79479.51257.2284.12111.57
Short Term Debt Incl. Current Port. of LT Debt1.230.920.890.860.830.81
Accounts Payable0.000.000.000.000.000.00
Other Current Liabilities18.0613.3615.3417.7014.1512.18
Total Current Liabilities19.2914.2816.2318.5614.9812.98
Long Term Debt0.764.674.915.145.375.59
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities20.0518.9521.1423.7120.3618.57
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.00507.69308.82308.82
Common Equity348.30399.83458.37-274.18-245.06-215.83
Total Shareholders Equity348.30399.83458.37233.5263.7693.00
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity348.30399.83458.37233.5263.7693.00
Total Liabilities & Stockholders Equity368.35418.79479.51257.2284.12111.57
Book Value Per Share7.678.8410.41-6.04-5.92-5.21
Tangible Book Value Per Share7.678.8410.41-6.04-5.92-5.21
Full-Time Employees--133114109103
Price to Book Ratio0.971.95-2.91-2.97--
Return on Assets-101.59-75.23----
Return on Equity-111.55-80.95----
Return on Invested Capital-17.24-15.00-17.17-12.33-43.17-22.66
Quick Ratio16.5222.9120.0113.224.897.57
Current Ratio16.5222.9120.0113.224.897.57

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-60.19-60.67-79.55-29.42-29.85-22.34
Depreciation0.150.160.140.140.140.17
Other Funds (Non Cash)7.849.0534.30-0.120.920.17
Funds from Operations-52.20-51.45-45.11-29.40-28.79-22.01
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital7.330.27-1.72-2.39-5.18-3.54
Cash from Operating Activities-44.87-51.18-46.83-31.79-33.97-25.55
Capital Expenditures-0.02-0.02-0.38-0.03-0.070.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments60.7367.03-242.18-135.5617.5037.50
Purchase of Investments-19.770.00-266.18-142.060.000.00
Sale Or Maturity of Investments80.5067.0324.006.5017.5037.50
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities60.7067.01-242.55-135.5917.4337.50
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.090.65275.86198.970.000.01
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.090.65275.86198.970.000.01
Proceedsfrom Stock Options0.650.00275.69198.870.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-7.50-3.89-0.92-0.16-0.05
Other Financing Activities Uses0.00-7.50-3.89-0.92-0.16-0.05
Cash from Financing Activities0.09-6.85271.96198.06-0.16-0.05
Net Change in Cash15.938.98-17.4230.68-16.6911.90
Free Cash Flow-44.89-51.20-47.20-31.82-34.03-25.55

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3026.63%3.3M12.2M518.84K
2026-10-1527.21%3.3M12.2M834.38K
2026-09-3026.08%3.1M12.1M859.36K
2026-09-1528.77%3.3M11.5M878.14K
2026-08-3129.90%3.4M11.5M829.27K
2026-08-14119.85%3.2M2.7M779.51K
2026-07-3142.84%3.6M8.4M724.70K
2026-07-1546.82%3.6M7.7M393.98K
2026-06-3033.65%2.6M7.7M353.37K
2026-06-1524.60%1.9M7.7M299.34K
2026-05-2920.64%1.6M7.6M275.26K
2026-05-1518.07%1.4M7.5M251.57K
2026-04-3022.05%1.7M7.9M242.30K
2026-04-1522.17%1.7M7.6M216.84K
2026-03-3112.35%1.4M11.5M197.33K
2026-03-1311.07%1.4M12.3M228.87K
2026-02-2711.04%1.4M12.3M258.72K
2026-02-1311.20%1.4M12.3M268.91K
2026-01-306.77%1.3M18.8M280.47K
2026-01-155.31%1.1M20.4M357.56K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.503.107.100.0018.0000.000.000.966-0.0920.001
call5.001.104.000.006.4900.000.000.951-0.0130.001
call7.500.002.100.004.3300.000.000.692-0.1400.004
call10.000.000.250.252.54119.000.000.309-0.0560.004
call12.500.003.900.052.6451.000.000.173-0.0450.003
call15.000.000.850.104.03135.000.000.233-0.0770.004
call17.500.001.952.263.7312.000.000.137-0.0550.003
call20.000.001.950.004.1260.000.000.128-0.0580.003
call22.500.001.951.954.4831.000.000.122-0.0610.002
call25.000.001.950.004.7400.000.000.117-0.0630.002
call30.000.001.9514.505.2271.000.000.110-0.0660.002
call35.000.001.9513.005.6242.000.000.105-0.0690.002
call40.000.001.950.056.0181620.000.102-0.0710.002
call45.000.001.950.056.30531.000.000.099-0.0730.002
call50.000.001.950.006.4990.000.000.096-0.0750.002
call55.000.000.200.256.36115.000.000.081-0.0600.002
put2.500.002.950.004.1540.000.00-0.021-0.0140.001
put5.000.000.050.1012.26570.000.00-0.116-0.1610.002
put7.500.002.950.736.71415.000.00-0.309-0.1380.004
put10.000.754.802.706.9161.000.00-0.776-0.0350.004
put12.503.106.905.507.06441.000.00-0.827-0.0440.003
put15.005.409.906.558.5530.000.00-0.850-0.0490.003
put17.508.0012.004.508.4080.000.00-0.783-0.0810.004
put20.0010.4014.800.009.3910.000.00-0.871-0.0560.003
put22.5013.0017.000.008.9520.000.00-0.877-0.0580.002
put25.0015.4020.000.0010.5600.000.00-0.882-0.0600.002
put30.0020.4024.800.0010.5170.000.00-0.888-0.0630.002
put35.0025.4030.000.0011.4150.000.00-0.893-0.0650.002
put40.0030.4035.000.0011.8110.000.00-0.897-0.0670.002
put45.0035.4039.800.0011.7250.000.00-0.899-0.0680.002
put50.0040.4045.000.0012.7040.000.00-0.903-0.0690.002
put55.0045.4049.800.0012.2930.000.00-0.919-0.0580.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-164Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-15144Filing for proposed sale of securities under Rule 144.SEC
2026-10-15144Filing for proposed sale of securities under Rule 144.SEC
2026-10-15144Filing for proposed sale of securities under Rule 144.SEC
2026-10-15144Filing for proposed sale of securities under Rule 144.SEC
2026-10-15144Filing for proposed sale of securities under Rule 144.SEC
2026-10-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-23EFFECTEffectiveness filing by commission orderSEC
2026-09-23424B3SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-18S-1/ASEC
2026-09-16144Filing for proposed sale of securities under Rule 144.SEC
2026-09-09S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-08-20SCHEDULE 13GSEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-18SCHEDULE 13D/ASEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-08-03SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10001.06M6
2026-0900192.66K1
2026-0850.07M1276.91K1
2026-0715.46M411.18M18
2026-060000
2026-050011.45M20
2026-04004.71M16
2026-030000
2026-02693.85K4732.22K8
2026-0100635.86K3
2025-120000
2025-110000

Institutional holders

Manager% owned
Novo Holdings A/S8.65%
FCPM III SERVICES B.V.7.57%
T. Rowe Price Investment Management, Inc.6.53%
GOLDMAN SACHS GROUP INC4.57%
PRICE T ROWE ASSOCIATES INC /MD/3.34%
FMR LLC2.92%
BlackRock, Inc.2.41%
Nan Fung Group Holdings Ltd2.28%
5AM Venture Management, LLC2.23%
STATE STREET CORP2.00%

Funds

Fund% owned
T. Rowe Price Small-Cap Stock Fund, Inc.1.47%
T. Rowe Price Small-Cap Value Fund, Inc.1.42%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.30%
State Street(R) SPDR(R) S&P(R) Biotech ETF1.17%
Fidelity Stock Selector Small Cap Fund0.95%
SMALLCAP World Fund Inc0.95%
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund0.95%
T. Rowe Price New Horizons Fund, Inc.0.94%
T. Rowe Price Institutional Small-Cap Stock Fund0.80%
iShares Russell 2000 ETF0.63%

OakChart. MPLT. Cached 15 minutes.